Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States.

Jing Voon ChenTimothy M KleinJeffrey NesheimPaul N Mudd

Published in: Journal of medical economics (2022)

Vibegron is cost-effective from a commercial payor (WTP threshold $150,000/QALY) and Medicare (WTP threshold $100,000/QALY) perspective when compared with other oral pharmacologic treatments for OAB.

Keyphrases

combination therapy
health insurance
affordable care act